Name (Synonyms) | Correlation | |
---|---|---|
drug255 | Awake Prone Positioning Wiki | 1.00 |
drug2314 | Standard care Wiki | 0.38 |
Name (Synonyms) | Correlation | |
---|---|---|
D011665 | Pulmonary Valve Insufficiency NIH | 0.41 |
D008171 | Lung Diseases, NIH | 0.26 |
D013577 | Syndrome NIH | 0.11 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.10 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.09 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0010444 | Pulmonary insufficiency HPO | 0.41 |
HP:0002088 | Abnormal lung morphology HPO | 0.26 |
There is one clinical trial.
The necessity for early detection and hence improving the outcome of treatment of pneumonia is critical especially SARS-CoV-2 induced cases. This work was designed to evaluate the potential application of measuring circulating epigenetic markers namely, miR-744, miR-24, miR-124, miR-155, miR-19a, miR-122, miR-21, miR-223, let-7f, miR-146, miR-196, miR-136, P13-K, miR-9 expression, and DNA methylation profiling of the ACE2, TMPRSS2, PARP, HOX1 genes in Coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 with/without pneumonia and severe acute respiratory syndrome (SARS) patients as an attempt to evaluate the potential benefits of these new circulating, prognostic, epigenetic markers for Turkish patients.
Description: Analysis of pathway-related micro RNAs in patients with mild, moderate and severe Covid 19 clinics
Measure: Determination of the relationship between the severity of disease and epigenetic factors in COVID 19 Time: Seven months